The blockbuster diabetes and weight loss drug semaglutide (Wegovy, Ozempic, Rybelsus) reduced the relative risk of heart attack, stroke, or cardiovascular deaths by 20 percent in high-risk patients with cardiovascular disease but not diabetes during a large and long randomized, placebo-controlled trial.
People on semaglutide in the trial lost an average of 9.5 percent of their body weight, an 8.5 percentage-point drop over those in the placebo group.
Perhaps the largest [caveat] is that while the trial was large, with 17,604 participants, it did not enroll a diverse group of participants. Most were white (84 percent) and male (72 percent).
[
add
]
[
|
|
...
]